The role of gut hormones and the hypothalamus in appetite regulation

Endocrine Journal

Volumn 57, Issue 5, 2010, Pages 359-372

  Suzuki, Keisuke ^a   Simpson, Katherine A ^a   Minnion, James S ^a   Shillito, Joyceline C ^a   Bloom, Stephen R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Appetite; Gut hormone; Hypothalamus

Indexed keywords

AMYLIN; CHOLECYSTOKININ; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; INSULIN; LEPTIN; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY [3-36];

APPETITE; BODY WEIGHT; BRAIN STEM; FOOD INTAKE; GASTROINTESTINAL TRACT; HUMAN; HYPOTHALAMUS; NONHUMAN; OBESITY; REVIEW; REWARD;

ADULT; ANIMALS; APPETITE REGULATION; BRAIN STEM; FEEDING BEHAVIOR; GASTROINTESTINAL HORMONES; GASTROINTESTINAL TRACT; HUMANS; HYPOTHALAMUS; MODELS, BIOLOGICAL; OBESITY; REWARD;

EID: 77953630340     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-077     Document Type: Review

References (165)

1. Zaninotto P, Head J, Stamatakis E, Wardle H, Mindell J (2009) Trends in obesity among adults in England from 1993 to 2004 by age and social class and projections of prevalence to 2012. J Epidemiol Community Health 63: 140-146.
2. WHO (2008) Obesity.
3. Matsushita Y, Takahashi Y, Mizoue T, Inoue M, Noda M, Tsugane S (2008) Overweight and obesity trends among Japanese adults: a 10-year follow-up of the JPHC Study. Int J Obes (Lond) 32: 1861-1867.
4. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz GA (2001) Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 161: 1581-1586.
5. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH (1999) The disease burden associated with overweight and obesity. JAMA 282: 1523-1529.
6. Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, Serraino D, Franceschi S, Talamini R (2009) The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 20: 353-357.
7. Shah N, Roux F (2009) The relationship of obesity and obstructive sleep apnea. Clin Chest Med 30: 455-465, vii.
8. Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J (2006) Body mass index and the risk of Parkinson disease. Neurology 67: 1955-1959.
9. Whitmer RA, Gunderson EP, Quesenberry CP, Jr., Zhou J, Yaffe K (2007) Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res 4: 103-109.
10. Wilding JP (2002) Neuropeptides and appetite control. Diabet Med 19: 619-627.
11. Farooqi S, O'Rahilly S (2006) Genetics of obesity in humans. Endocr Rev 27: 710-718.
12. Hinney A, Vogel CI, Hebebrand J. (2010) From monogenic to polygenic obesity: recent advances. Eur Child Adolesc Psychiatry in press.
13. Yanovski SZ, Yanovski JA (2002) Obesity. N Engl J Med 346: 591-602.
14. Brolin RE (2002) Bariatric surgery and long-term control of morbid obesity. JAMA 288: 2793-2796.
15. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346: 1623-1630.
16. Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R, Taveras C, Schrope B, Bessler M (2009) Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Rouxen-Y gastric bypass. Int J Obes (Lond) 33: 786-795.
17. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lonroth H, Fandriks L, Ghatei MA, Bloom SR, Olbers T (2007) Gut hormones as mediators of appetite and weight loss after Rouxen-Y gastric bypass. Ann Surg 246: 780-785.
18. Chaudhri OB, Wynne K, Bloom SR (2008) Can gut hormones control appetite and prevent obesity? Diabetes Care 31 Suppl 2: S284-289.
19. Field BC, Chaudhri OB, Bloom SR (2009) Obesity treatment: novel peripheral targets. Br J Clin Pharmacol 68: 830-843.
20. Mayer J, Thomas DW (1967) Regulation of food intake and obesity. Science 156: 328-337.
21. Gross PM (1992) Circumventricular organ capillaries. Prog Brain Res 91: 219-233.
22. Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404: 661-671.
23. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131-141.
24. Tao YX (2005) Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol Cell Endocrinol 239: 1-14.
25. Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, Inouye M, Freathy RM, Attwood AP, Beckmann JS, Berndt SI, Jacobs KB, Chanock SJ, Hayes RB, Bergmann S, Bennett AJ, Bingham SA, Bochud M, Brown M, Cauchi S, Connell JM, Cooper C, Smith GD, Day I, Dina C, De S, Dermitzakis ET, Doney AS, Elliott KS, Elliott P, Evans DM, Sadaf Farooqi I, Froguel P, Ghori J, Groves CJ, Gwilliam R, Hadley D, Hall AS, Hattersley AT, Hebebrand J, Heid IM, Lamina C, Gieger C, Illig T, Meitinger T, Wichmann HE, Herrera B, Hinney A, Hunt SE, Jarvelin MR, Johnson T, Jolley JD, Karpe F, Keniry A, Khaw KT, Luben RN, Mangino M, Marchini J, McArdle WL, McGinnis R, Meyre D, Munroe PB, Morris AD, Ness AR, Neville MJ, Nica AC, Ong KK, O'Rahilly S, Owen KR, Palmer CN, Papadakis K, Potter S, Pouta A, Qi L, Randall JC, Rayner NW, Ring SM, Sandhu MS, Scherag A, Sims MA, Song K, Soranzo N, Speliotes EK, Syddall HE, Teichmann SA, Timpson NJ, Tobias JH, Uda M, Vogel CI, Wallace C, Waterworth DM, Weedon MN, Willer CJ, Wraight, Yuan X, Zeggini E, Hirschhorn JN, Strachan DP, Ouwehand WH, Caulfield MJ, Samani NJ, Frayling TM, Vollenweider P, Waeber G, Mooser V, Deloukas P, McCarthy MI, Wareham NJ, Barroso I, Kraft P, Hankinson SE, Hunter DJ, Hu FB, Lyon HN, Voight BF, Ridderstrale M, Groop L, Scheet P, Sanna S, Abecasis GR, Albai G, Nagaraja R, Schlessinger D, Jackson AU, Tuomilehto J, Collins FS, Boehnke M, Mohlke KL (2008) Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 40: 768-775.
26. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, Rosenblum CI, Vongs A, Feng Y, Cao L, Metzger JM, Strack AM, Camacho RE, Mellin TN, Nunes CN, Min W, Fisher J, Gopal-Truter S, MacIntyre DE, Chen HY, Van der Ploeg LH (2000) Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 26: 97-102.
27. Abbott CR, Rossi M, Kim M, AlAhmed SH, Taylor GM, Ghatei MA, Smith DM, Bloom SR (2000) Investigation of the melanocyte stimulating hormones on food intake. Lack Of evidence to support a role for the melanocortin-3-receptor. Brain Res 869: 203-210.
28. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, Clausen JT, Jensen PB, Madsen OD, Vrang N, Larsen PJ, Hastrup S (1998) Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393: 72-76.
29. Abbott CR, Rossi M, Wren AM, Murphy KG, Kennedy AR, Stanley SA, Zollner AN, Morgan DG, Morgan I, Ghatei MA, Small CJ, Bloom SR (2001) Evidence of an orexigenic role for cocaine- and amphetamine-regulated transcript after administration into discrete hypothalamic nuclei. Endocrinology 142: 3457-3463.
30. Clark JT, Kalra PS, Crowley WR, Kalra SP (1984) Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115: 427-429.
31. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF (1986) Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 7: 1189-1192.
32. Roseberry AG, Liu H, Jackson AC, Cai X, Friedman JM (2004) Neuropeptide Y-mediated inhibition of proopiomelanocortin neurons in the arcuate nucleus shows enhanced desensitization in ob/ob mice. Neuron 41: 711-722.
33. Rossi M, Kim MS, Morgan DG, Small CJ, Edwards CM, Sunter D, Abusnana S, Goldstone AP, Russell SH, Stanley SA, Smith DM, Yagaloff K, Ghatei MA, Bloom SR (1998) A C-terminal fragment of Agoutirelated protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology 139: 4428-4431.
34. Belgardt BF, Okamura T, Bruning JC (2009) Hormone and glucose signalling in POMC and AgRP neurons. J Physiol 587: 5305-5314.
35. Leibowitz SF, Hammer NJ, Chang K (1981) Hypothalamic paraventricular nucleus lesions produce overeating and obesity in the rat. Physiol Behav 27: 1031-1040.
36. Wynne K, Stanley S, McGowan B, Bloom S (2005) Appetite control. J Endocrinol 184: 291-318.
37. Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR, Tecott LH, Reichardt LF (2003) Brainderived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 6: 736-742.
38. Unger TJ, Calderon GA, Bradley LC, Sena-Esteves M, Rios M (2007) Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J Neurosci 27: 14265-14274.
39. Bailey EF (2008) A tasty morsel: the role of the dorsal vagal complex in the regulation of food intake and swallowing. Focus on "BDNF/TrkB signaling interacts with GABAergic system to inhibit rhythmic swallowing in the rat," by Bariohay et al. Am J Physiol Regul Integr Comp Physiol 295: R1048-1049.
40. Schwartz GJ (2000) The role of gastrointestinal vagal afferents in the control of food intake: current prospects. Nutrition 16: 866-873.
41. Schwartz GJ, Salorio CF, Skoglund C, Moran TH (1999) Gut vagal afferent lesions increase meal size but do not block gastric preload-induced feeding suppression. Am J Physiol 276: R1623-1629.
42. Moriarty P, Dimaline R, Thompson DG, Dockray GJ (1997) Characterization of cholecystokininA and cholecystokininB receptors expressed by vagal afferent neurons. Neuroscience 79: 905-913.
43. Burdyga G, Spiller D, Morris R, Lal S, Thompson DG, Saeed S, Dimaline R, Varro A, Dockray GJ (2002) Expression of the leptin receptor in rat and human nodose ganglion neurones. Neuroscience 109: 339-347.
44. Koda S, Date Y, Murakami N, Shimbara T, Hanada T, Toshinai K, Niijima A, Furuya M, Inomata N, Osuye K, Nakazato M (2005) The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146: 2369-2375.
45. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, Kigoshi T, Nakayama K, Uchida K (2004) Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110: 36-43.
46. Nelson DW, Sharp JW, Brownfield MS, Raybould HE, Ney DM (2007) Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. Endocrinology 148: 1954-1962.
47. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato M (2002) The role of the gastric afferent vagal nerve in ghrelininduced feeding and growth hormone secretion in rats. Gastroenterology 123: 1120-1128.
48. Burdyga G, Lal S, Spiller D, Jiang W, Thompson D, Attwood S, Saeed S, Grundy D, Varro A, Dimaline R, Dockray GJ (2003) Localization of orexin-1 receptors to vagal afferent neurons in the rat and humans. Gastroenterology 124: 129-139.
49. Grill HJ, Kaplan JM (2002) The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 23: 2-40.
50. Ellacott KL, Halatchev IG, Cone RD (2006) Characterization of leptin-responsive neurons in the caudal brainstem. Endocrinology 147: 3190-3195.
51. Cota D, Tschop MH, Horvath TL, Levine AS (2006) Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev 51: 85-107.
52. Zhang M, Gosnell BA, Kelley AE (1998) Intake of high-fat food is selectively enhanced by mu opioid receptor stimulation within the nucleus accumbens. J Pharmacol Exp Ther 285: 908-914.
53. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822-825.
54. Rehfeld JF (1998) The new biology of gastrointestinal hormones. Physiol Rev 78: 1087-1108.
55. Martin CK, Bellanger DE, Rau KK, Coulon S, Greenway FL (2007) Safety of the Ullorex oral intragastric balloon for the treatment of obesity. J Diabetes Sci Technol 1: 574-581.
56. Rigaud D, Trostler N, Rozen R, Vallot T, Apfelbaum M (1995) Gastric distension, hunger and energy intake after balloon implantation in severe obesity. Int J Obes Relat Metab Disord 19: 489-495.
57. Fernandes M, Atallah AN, Soares BG, Humberto S, Guimaraes S, Matos D, Monteiro L, Richter B (2007) Intragastric balloon for obesity. Cochrane Database Syst Rev: CD004931.
58. Tatemoto K, Mutt V (1980) Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285: 417-418.
59. Lin S, Boey D, Herzog H (2004) NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides 38: 189-200.
60. Eberlein GA, Eysselein VE, Schaeffer M, Layer P, Grandt D, Goebell H, Niebel W, Davis M, Lee TD, Shively JE, Reeve JR, Jr (1989) A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36). Peptides 10: 797-803.
61. Keire DA, Bowers CW, Solomon TE, Reeve JR, Jr. (2002) Structure and receptor binding of PYY analogs. Peptides 23: 305-321.
62. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89: 1070-1077.
63. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650-654.
64. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349: 941-948.
65. Boey D, Lin S, Enriquez RF, Lee NJ, Slack K, Couzens M, Baldock PA, Herzog H, Sainsbury A (2008) PYY transgenic mice are protected against diet-induced and genetic obesity. Neuropeptides 42: 19-30.
66. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL (2005) Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146: 3748-3756.
67. Kim BJ, Carlson OD, Jang HJ, Elahi D, Berry C, Egan JM (2005) Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab 90: 6665-6671.
68. Pfluger PT, Kampe J, Castaneda TR, Vahl T, D'Alessio DA, Kruthaupt T, Benoit SC, Cuntz U, Rochlitz HJ, Moehlig M, Pfeiffer AF, Koebnick C, Weickert MO, Otto B, Spranger J, Tschop MH (2007) Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 92: 583-588.
69. Alvarez Bartolome M, Borque M, Martinez-Sarmiento J, Aparicio E, Hernandez C, Cabrerizo L, Fernandez-Represa JA (2002) Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 12: 324-327.
70. Misra M, Miller KK, Tsai P, Gallagher K, Lin A, Lee N, Herzog DB, Klibanski A (2006) Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 91: 1027-1033.
71. Ashby D, Bloom SR (2007) Recent progress in PYY research--an update report for 8th NPY meeting. Peptides 28: 198-202.
72. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, Bloom SR (2005) The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstemhypothalamic pathway. Brain Res 1044: 127-131.
73. Morley JE, Levine AS, Grace M, Kneip J (1985) Peptide YY (PYY), a potent orexigenic agent. Brain Res 341: 200-203.
74. Stanley BG, Daniel DR, Chin AS, Leibowitz SF (1985) Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides 6: 1205-1211.
75. Kanatani A, Mashiko S, Murai N, Sugimoto N, Ito J, Fukuroda T, Fukami T, Morin N, MacNeil DJ, Van der Ploeg LH, Saga Y, Nishimura S, Ihara M (2000) Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 141: 1011-1016.
76. Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, Fujino MA, Niijima A, Meguid MM, Kasuga M (2003) Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124: 1325-1336.
77. Parker RM, Herzog H (1999) Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci 11: 1431-1448.
78. Whitcomb DC, Taylor IL, Vigna SR (1990) Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. Am J Physiol 259: G687-691.
79. Jorde R, Burhol PG (1984) Fasting and postprandial plasma pancreatic polypeptide (PP) levels in obesity. Int J Obes 8: 393-397.
80. Wisen O, Bjorvell H, Cantor P, Johansson C, Theodorsson E (1992) Plasma concentrations of regulatory peptides in obesity following modified sham feeding (MSF) and a liquid test meal. Regul Pept 39: 43-54.
81. Glaser B, Zoghlin G, Pienta K, Vinik AI (1988) Pancreatic polypeptide response to secretin in obesity: effects of glucose intolerance. Horm Metab Res 20: 288-292.
82. Lassmann V, Vague P, Vialettes B, Simon MC (1980) Low plasma levels of pancreatic polypeptide in obesity. Diabetes 29: 428-430.
83. Asakawa A, Inui A, Ueno N, Fujimiya M, Fujino MA, Kasuga M (1999) Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 20: 1445-1448.
84. Ueno N, Inui A, Iwamoto M, Kaga T, Asakawa A, Okita M, Fujimiya M, Nakajima Y, Ohmoto Y, Ohnaka M, Nakaya Y, Miyazaki JI, Kasuga M (1999) Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 117: 1427-1432.
85. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, Bloom SR (2003) Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88: 3989-3992.
86. Holst JJ (2004) On the physiology of GIP and GLP-1. Horm Metab Res 36: 747-754.
87. Tang-Christensen M, Vrang N, Larsen PJ (2001) Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 25 Suppl 5: S42-47.
88. Tucker JD, Dhanvantari S, Brubaker PL (1996) Proglucagon processing in islet and intestinal cell lines. Regul Pept 62: 29-35.
89. Egan JM, Bulotta A, Hui H, Perfetti R (2003) GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 19: 115-123.
90. Deacon CF (2004) Circulation and degradation of GIP and GLP-1. Horm Metab Res 36: 761-765.
91. Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835.
92. Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88: 220-224.
93. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539.
94. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439.
95. Yamato E, Ikegami H, Takekawa K, Fujisawa T, Nakagawa Y, Hamada Y, Ueda H, Ogihara T (1997) Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1). Horm Metab Res 29: 56-59.
96. Vahl TP, Drazen DL, Seeley RJ, D'Alessio DA, Woods SC (2010) Meal-anticipatory glucagon-like peptide-1 secretion in rats. Endocrinology 151: 569-575.
97. Cummings DE, Overduin J (2007) Gastrointestinal regulation of food intake. J Clin Invest 117: 13-23.
98. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A (2001) A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86: 4382-4389.
99. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267: 7402-7405.
100. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092-1100.
101. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39-47.
102. Drucker DJ (1999) Glucagon-like Peptide 2. Trends Endocrinol Metab 10: 153-156.
103. Schmidt PT, Naslund E, Gryback P, Jacobsson H, Hartmann B, Holst JJ, Hellstrom PM (2003) Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 116: 21-25.
104. Drucker DJ, Erlich P, Asa SL, Brubaker PL (1996) Induction of intestinal epithelial proliferation by glucagonlike peptide 2. Proc Natl Acad Sci U S A 93: 7911-7916.
105. Wallis K, Walters JR, Forbes A (2007) Review article: glucagon-like peptide 2--current applications and future directions. Aliment Pharmacol Ther 25: 365-372.
106. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG (2009) Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis.
107. Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ (2004) Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 39: 353-358.
108. Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, Bloom SR (1983) Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 57: 488-495.
109. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88: 4696-4701.
110. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, Bloom SR (2001) Oxyntomodulin inhibits food intake in the rat. Endocrinology 142: 4244-4250.
111. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR (2006) Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomized controlled trial. Int J Obes (Lond) 30: 1729-1736.
112. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145: 2687-2695.
113. Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004) Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127: 546-558.
114. Sowden GL, Drucker DJ, Weinshenker D, Swoap SJ (2007) Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. Am J Physiol Regul Integr Comp Physiol 292: R962-970.
115. Ban K, Kim KH, Cho CK, Sauve M, Diamandis EP, Backx PH, Drucker DJ, Husain M (2010) Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor. Endocrinology in press.
116. Druce MR, Minnion JS, Field BC, Patel SR, Shillito JC, Tilby M, Beale KE, Murphy KG, Ghatei MA, Bloom SR (2009) Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs. Endocrinology 150: 1712-1722.
117. Chan EK, Mackey MA, Snover DC, Schneider PD, Rucker RD, Jr., Allen CE, Buchwald H (1984) Suppression of weight gain by glucagon in obese Zucker rats. Exp Mol Pathol 40: 320-327.
118. Geary N, Le Sauter J, Noh U (1993) Glucagon acts in the liver to control spontaneous meal size in rats. Am J Physiol 264: R116-122.
119. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N, Holland J, Hembree J, Abplanalp W, Grant E, Ruehl J, Wilson H, Kirchner H, Lockie SH, Hofmann S, Woods SC, Nogueiras R, Pfluger PT, Perez-Tilve D, DiMarchi R, Tschop MH (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5: 749-757.
120. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, SinhaRoy R (2009) Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58: 2258-2266.
121. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormonereleasing acylated peptide from stomach. Nature 402: 656-660.
122. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50: 1714-1719.
123. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S (2001) A role for ghrelin in the central regulation of feeding. Nature 409: 194-198.
124. Tschop M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407: 908-913.
125. Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnert P, Fichter M, Tschop M (2001) Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 145: 669-673.
126. le Roux CW, Patterson M, Vincent RP, Hunt C, Ghatei MA, Bloom SR (2005) Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab 90: 1068-1071.
127. Wang L, Saint-Pierre DH, Tache Y (2002) Peripheral ghrelin selectively increases Fos expression in neuropeptide Y - synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci Lett 325: 47-51.
128. Chen HY, Trumbauer ME, Chen AS, Weingarth DT, Adams JR, Frazier EG, Shen Z, Marsh DJ, Feighner SD, Guan XM, Ye Z, Nargund RP, Smith RG, Van der Ploeg LH, Howard AD, MacNeil DJ, Qian S (2004) Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 145: 2607-2612.
129. Lawrence CB, Snape AC, Baudoin FM, Luckman SM (2002) Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 143: 155-162.
130. Gibbs J, Young RC, Smith GP (1973) Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 84: 488-495.
131. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA (1985) Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 75: 1144-1152.
132. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP (1981) C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 34: 154-160.
133. Wank SA (1995) Cholecystokinin receptors. Am J Physiol 269: G628-646.
134. Moran TH, Baldessarini AR, Salorio CF, Lowery T, Schwartz GJ (1997) Vagal afferent and efferent contributions to the inhibition of food intake by cholecysto kinin. Am J Physiol 272: R1245-1251.
135. Moran TH, Katz LF, Plata-Salaman CR, Schwartz GJ (1998) Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Physiol 274: R618-625.
136. West DB, Fey D, Woods SC (1984) Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 246: R776-787.
137. Crawley JN, Beinfeld MC (1983) Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302: 703-706.
138. Reda TK, Geliebter A, Pi-Sunyer FX (2002) Amylin, food intake, and obesity. Obes Res 10: 1087-1091.
139. Reinehr T, de Sousa G, Niklowitz P, Roth CL (2007) Amylin and its relation to insulin and lipids in obese children before and after weight loss. Obesity (Silver Spring) 15: 2006-2011.
140. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC (2000) Amylin: a novel action in the brain to reduce body weight. Endocrinology 141: 850-853.
141. Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG (1998) Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care 21: 987-993.
142. Polonsky KS, Given BD, Van Cauter E (1988) Twentyfour-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81: 442-448.
143. Pardridge WM, Eisenberg J, Yang J (1985) Human blood-brain barrier insulin receptor. J Neurochem 44: 1771-1778.
144. Marks JL, Porte D, Jr., Stahl WL, Baskin DG (1990) Localization of insulin receptor mRNA in rat brain by in situ hybridization. Endocrinology 127: 3234-3236.
145. Air EL, Benoit SC, Blake Smith KA, Clegg DJ, Woods SC (2002) Acute third ventricular administration of insulin decreases food intake in two paradigms. Pharmacol Biochem Behav 72: 423-429.
146. Porte D, Jr., Woods SC (1981) Regulation of food intake and body weight in insulin. Diabetologia 20 Suppl: 274-280.
147. Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L (2002) Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 5: 566-572.
148. Schwartz MW, Sipols AJ, Marks JL, Sanacora G, White JD, Scheurink A, Kahn SE, Baskin DG, Woods SC, Figlewicz DP (1992) Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology 130: 3608-3616.
149. Benoit SC, Air EL, Coolen LM, Strauss R, Jackman A, Clegg DJ, Seeley RJ, Woods SC (2002) The catabolic action of insulin in the brain is mediated by melanocortins. J Neurosci 22: 9048-9052.
150. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432.
151. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF (1996) Serum immunoreactive- leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292-295.
152. Saad MF, Riad-Gabriel MG, Khan A, Sharma A, Michael R, Jinagouda SD, Boyadjian R, Steil GM (1998) Diurnal and ultradian rhythmicity of plasma leptin: effects of gender and adiposity. J Clin Endocrinol Metab 83: 453-459.
153. Schoeller DA, Cella LK, Sinha MK, Caro JF (1997) Entrainment of the diurnal rhythm of plasma leptin to meal timing. J Clin Invest 100: 1882-1887.
154. Korbonits M, Trainer PJ, Little JA, Edwards R, Kopelman PG, Besser GM, Svec F, Grossman AB (1997) Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary-adrenal activity. Clin Endocrinol (Oxf) 46: 751-757.
155. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM (1996) Leptin enters the brain by a saturable system independent of insulin. Peptides 17: 305-311.
156. Baskin DG, Breininger JF, Schwartz MW (1999) Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Diabetes 48: 828-833.
157. Sahu A (2003) Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol 24: 225-253.
158. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269: 540-543.
159. Fei H, Okano HJ, Li C, Lee GH, Zhao C, Darnell R, Friedman JM (1997) Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci U S A 94: 7001-7005.
160. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP (1996) Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84: 491-495.
161. Coleman DL (1978) Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 14: 141-148.
162. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM (1995) Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269: 543-546.
163. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI, DePaoli AM, O'Rahilly S (2002) Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110: 1093-1103.
164. Munzberg H (2010) Leptin-Signaling Pathways and Leptin Resistance. Forum Nutr 63: 123-132.
165. Banks WA (2001) Anorectic effects of circulating cytokines: role of the vascular blood-brain barrier. Nutrition 17: 434-437.